嵌合抗原受体
免疫疗法
医学
T细胞
临床试验
抗原
免疫学
食品药品监督管理局
癌症免疫疗法
癌症研究
免疫系统
内科学
药理学
作者
Mathew G. Angelos,Ruchi P. Patel,Marco Ruella,Stefan K. Barta
标识
DOI:10.1016/j.jtct.2023.10.013
摘要
Chimeric antigen receptor T cell (CAR-T) immunotherapy has revolutionized the treatment of relapsed and refractory B cell-derived hematologic malignancies. Currently, there are 6 Food and Drug Administration-approved commercial CAR-T products that target antigens exclusively expressed on malignant B cells or plasma cells. However, concurrent advancement for patients with rarer and more aggressive T cell-derived hematologic malignancies have not yet been achieved. CAR-T immunotherapies are uniquely limited by challenges related to CAR-T product manufacturing and intrinsic tumor biology. In this review tailored for practicing clinician-scientists, we discuss the major barriers of CAR-T implementation against T cell-derived neoplasms and highlight specific scientific advancements poised to circumvent these obstacles. We summarize salient early-stage clinical trials implementing novel CAR-T immunotherapies specifically for patients with relapsed and/or refractory T cell neoplasms. Finally, we highlight novel manufacturing and treatment strategies that are poised to have a meaningful future clinical impact.
科研通智能强力驱动
Strongly Powered by AbleSci AI